
Obesity
Latest Content
Latest Videos

Shorts










Podcasts
More News

In this Q&A, Rob Stransky of NiceRx explains how to screen patients for gray-market retatrutide use and why cost drives demand for unregulated peptides.

Clinicians at Population Health Roundtables shared obesity care innovations, from pharmacist-led models to same-day liver screening

Clinicians at an AJMC roundtable in Cleveland said Medicare's GLP-1 Bridge came late and that cost and capacity gaps persist.

Many patients who stop a GLP-1 RA regain weight. How plans can measure adherence when cash-pay fills go unseen.

In more than 250,000 adults with prediabetes and obesity, GLP-1 users had lower risks of type 2 diabetes, death, and cardiovascular events.

Facing steep 2027 cost increases, employers are narrowing obesity drug coverage, while direct-to-employer models let them cap what they spend.

In TRANSCEND-T2D-2, retatrutide lowered A1C 2.2 points vs 1.8 with semaglutide 2 mg and more than doubled weight loss at 80 weeks.

Shields Health Solutions leaders say GLP-1 discontinuation is a support problem, not a medication problem, and pharmacist-led care can help close it.

Among nearly 48 million US adults eligible for obesity medications, oral semaglutide initiation climbed quickly after its December 2025 FDA approval.

Nearly 3 in 4 bariatric surgery candidates had clinical obesity, a phenotype that BMI alone did not distinguish from preclinical obesity.

In states that covered obesity-labeled GLP-1 RAs, total GLP-1 RA use rose less than obesity-labeled use alone, suggesting possible substitution.

A legal fight over a single amino acid could set retatrutide's exclusivity window, its Medicare negotiation clock, and its competitive future.

The triple agonist also lowered HbA1C by up to 1.6% over 80 weeks, with up to 40% of participants reaching normal levels.

Nonadherence to semaglutide for obesity worsened once out-of-pocket costs passed roughly $75 per 30-day supply among commercially insured adults.

An Endocrine Society scientific statement argues percent weight loss is an inadequate measure of obesity treatment success and proposes new targets.

Obesity care surges with GLP-1 demand, but fragmented ownership, prior authorizations, and coverage rules stall treatment—pharmacists step in.

GLP-1 prescribing among children aged 8 to 11 years with obesity rose 310-fold from 2019 to 2026, but use remains rare and unevenly distributed by income.

Updated systematic review finds GLP-1 therapies deliver substantial weight loss, with newer multiagonists and oral options expanding treatment choice.

At a Chicago roundtable, clinicians detailed fragmented obesity and diabetes care, transplant-access barriers, and insurance-driven prescribing decisions.

Atlanta clinicians described obesity care that stalls between routine diagnosis and delayed treatment, with coverage rules driving therapy choices.

Medicare Part D changes, premium stabilization expiration, and a Bridge demonstration converge with rising GLP-1 demand and costs.

Clinicians outline fragmented obesity and diabetes care models, insurance-driven prescribing, and early results from Medicare's GLP-1 bridge program.

Waist circumference (WC) predicts mortality risk in older adults independent of BMI, with high WC linked to 24% greater death risk, a new study finds.















